Skip to main content
SpringerLink
Log in

The Impact of Treating Chronic Liver Diseases on Hepatocellular Carcinoma Prevention

  • Chapter
  • First Online:
Primary Liver Cancer

Part of the book series: Clinical Gastroenterology ((CG))

  • 1445 Accesses

Abstract

Hepatocellular carcinoma (HCC) is the third most common cause of cancer death worldwide [1]. Chronic hepatitis B virus (HBV) infection is the single most important etiology that accounts for more than 52% of all the HCC cases globally [2]. Chronic hepatitis C virus (HCV) infection accounts for another 20–30%. Together, HBV and HCV cause approximately 80–85% of all HCC cases worldwide [3–6]. Another 10% of HCC can be attributed to alcohol and nonalcoholic steatohepatitis (NASH) [7–9]. Hereditary hemochromatosis (HH), autoimmune liver diseases, alpha-1 antitrypsin deficiency, Wilson’s disease, glycogen storage disease, porphyria, tyrosinemia, etc., contribute to the remaining 5–10% (Fig. 12.1a) [10, 11].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893–917.

    Article  PubMed  CAS  Google Scholar 

  2. El-Serag HB. Hepatocellular carcinoma: recent trends in the United States. Gastroenterology. 2004;127(5 Suppl 1):S27–34.

    Article  PubMed  Google Scholar 

  3. Yang JD, Roberts LR. Hepatocellular carcinoma: A global view. Nat Rev Gastroenterol Hepatol. 2010;7(8):448–58.

    Article  PubMed  Google Scholar 

  4. Sherman M. Epidemiology of hepatocellular carcinoma. Oncology. 2010;78 Suppl 1:7–10.

    Article  PubMed  Google Scholar 

  5. Nordenstedt H, White DL, El-Serag HB. The changing pattern of epidemiology in hepatocellular carcinoma. Dig Liver Dis. 2010;42 Suppl 3:S206–214.

    Article  PubMed  Google Scholar 

  6. Di Bisceglie AM. Hepatitis B and hepatocellular carcinoma. Hepatology. 2009;49(5 Suppl):S56–60.

    Article  PubMed  Google Scholar 

  7. Sherman M. Hepatocellular carcinoma: New and emerging risks. Dig Liver Dis. 2010;42 Suppl 3:S215–222.

    Article  PubMed  Google Scholar 

  8. El-Serag HB. Epidemiology of hepatocellular carcinoma in USA. Hepatol Res. 2007;37 Suppl 2:S88–94.

    Article  PubMed  Google Scholar 

  9. Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology. 2010;51(5):1820–32.

    Article  PubMed  Google Scholar 

  10. Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology. 2004;127(5 Suppl 1):S35–50.

    Article  PubMed  Google Scholar 

  11. Dragani TA. Risk of HCC: genetic heterogeneity and complex genetics. J Hepatol. 2010;52(2): 252–7.

    Article  PubMed  CAS  Google Scholar 

  12. Di Bisceglie AM, Lyra AC, Schwartz M, et al. Hepatitis C-related hepatocellular carcinoma in the United States: influence of ethnic status. Am J Gastroenterol. 2003;98(9):2060–3.

    Article  PubMed  Google Scholar 

  13. Marrero JA, Fontana RJ, Su GL, Conjeevaram HS, Emick DM, Lok AS. NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. Hepatology. 2002;36(6):1349–54.

    PubMed  Google Scholar 

  14. Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol. 2008;48(2):335–52.

    Article  PubMed  Google Scholar 

  15. Di Bisceglie AM. Hepatitis C and hepatocellular carcinoma. Hepatology. 1997;26(3 Suppl 1):34S–8S.

    Article  PubMed  Google Scholar 

  16. McMahon BJ. Natural history of chronic hepatitis B. Clin Liver Dis. 2010;14(3):381–96.

    Article  PubMed  Google Scholar 

  17. Wu HC, Wang Q, Yang HI, et al. Aflatoxin B1 exposure, hepatitis B virus infection, and hepatocellular carcinoma in Taiwan. Cancer Epidemiol Biomarkers Prev. 2009;18(3):846–53.

    Article  PubMed  CAS  Google Scholar 

  18. Colombo M, Donato MF. Prevention of hepatocellular carcinoma. Semin Liver Dis. 2005;25(2):155–61.

    Article  PubMed  Google Scholar 

  19. Chagas AL, Kikuchi LO, Oliveira CP, et al. Does hepatocellular carcinoma in non-alcoholic steatohepatitis exist in cirrhotic and non-cirrhotic patients? Br J Med Biol Res. 2009;42(10): 958–62.

    Article  CAS  Google Scholar 

  20. Takuma Y, Nouso K. Nonalcoholic steatohepatitis-associated hepatocellular carcinoma: our case series and literature review. World J Gastroenterol. 2010;16(12):1436–41.

    Article  PubMed  CAS  Google Scholar 

  21. Madhoun MF, Fazili J, Bright BC, Bader T, Roberts DN, Bronze MS. Hepatitis C prevalence in patients with hepatocellular carcinoma without cirrhosis. Am J Med Sci. 2010;339(2): 169–73.

    Article  PubMed  Google Scholar 

  22. Nzeako UC, Goodman ZD, Ishak KG. Hepatocellular carcinoma in cirrhotic and noncirrhotic livers. A clinico-histopathologic study of 804 North American patients. Am J Clin Pathol. 1996;105(1):65–75.

    PubMed  CAS  Google Scholar 

  23. Kew MC. Prevention of hepatocellular carcinoma. Ann Hepatol. 2005;9(2):120–32.

    Google Scholar 

  24. El-Serag HB. Hepatocellular carcinoma: an epidemiologic view. J Clin Gastroenterol. 2002;35(5 Suppl 2):S72–78.

    Article  PubMed  Google Scholar 

  25. Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol. 2004;130(7):417–22.

    Article  PubMed  Google Scholar 

  26. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53(3):1020–2.

    Article  PubMed  Google Scholar 

  27. Lok AS. Prevention of hepatitis B virus-related hepatocellular carcinoma. Gastroenterology. 2004;127(5 Suppl 1):S303–309.

    Article  PubMed  Google Scholar 

  28. Chang MH, You SL, Chen CJ, et al. Decreased incidence of hepatocellular carcinoma in hepatitis B vaccines: a 20-year follow-up study. J Natl Cancer Inst. 2009;101(19):1348–55.

    Article  PubMed  CAS  Google Scholar 

  29. Wichajarn K, Kosalaraksa P, Wiangnon S. Incidence of hepatocellular carcinoma in children in Khon Kaen before and after national hepatitis B vaccine program. Asian Pac J Cancer Prev. 2008;9(3):507–9.

    PubMed  Google Scholar 

  30. Lanier AP, Holck P, Ehrsam Day G, Key C. Childhood cancer among Alaska Natives. Pediatrics. 2003;112(5):e396.

    Article  PubMed  Google Scholar 

  31. Yang HI, Lu SN, Liaw YF, et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med. 2002;347(3):168–74.

    Article  PubMed  CAS  Google Scholar 

  32. Yu MW, Yeh SH, Chen PJ, et al. Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men. J Natl Cancer Inst. 2005;97(4):265–72.

    Article  PubMed  CAS  Google Scholar 

  33. Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. J Am Med Assoc. 2006;295(1):65–73.

    Article  CAS  Google Scholar 

  34. Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology. 2006;130(3):678–86.

    Article  PubMed  Google Scholar 

  35. Chen CJ, Iloeje UH, Yang HI. Long-term outcomes in hepatitis B: the REVEAL-HBV study. Clin Liver Dis. 2007;11(4):797–816. viii.

    Article  PubMed  Google Scholar 

  36. Lau DT, Bleibel W. Current status of antiviral therapy for hepatitis B. Ther Adv Gastroenterol. 2008;1(1):61–75.

    Article  Google Scholar 

  37. Lin SM, Sheen IS, Chien RN, Chu CM, Liaw YF. Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology. 1999;29(3):971–5.

    Article  PubMed  CAS  Google Scholar 

  38. Ikeda K, Kobayashi M, Saitoh S, et al. Significance of hepatitis B virus DNA clearance and early prediction of hepatocellular carcinogenesis in patients with cirrhosis undergoing interferon therapy: long-term follow up of a pilot study. J Gastroenterol Hepatol. 2005;20(1):95–102.

    Article  PubMed  CAS  Google Scholar 

  39. Sung JJ, Tsoi KK, Wong VW, Li KC, Chan HL. Meta-analysis: Treatment of hepatitis B infection reduces risk of hepatocellular carcinoma. Aliment Pharmacol Ther. 2008;28(9):1067–77.

    Article  PubMed  CAS  Google Scholar 

  40. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology. 2009;50(3):661–2.

    Article  PubMed  Google Scholar 

  41. Liaw YF. Impact of YMDD mutations during lamivudine therapy in patients with chronic hepatitis B. Antivir Chem Chemother. 2001;12 Suppl 1:67–71.

    PubMed  CAS  Google Scholar 

  42. Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med. 2004;351(15):1521–31.

    Article  PubMed  CAS  Google Scholar 

  43. Yuen MF, Seto WK, Chow DH, et al. Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease. Antivir Ther. 2007;12(8):1295–303.

    PubMed  CAS  Google Scholar 

  44. Matsumoto A, Tanaka E, Rokuhara A, et al. Efficacy of lamivudine for preventing hepatocellular carcinoma in chronic hepatitis B: A multicenter retrospective study of 2795 patients. Hepatol Res. 2005;32(3):173–84.

    Article  PubMed  CAS  Google Scholar 

  45. Di Marco V, Marzano A, Lampertico P, et al. Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine. Hepatology. 2004;40(4):883–91.

    Article  PubMed  Google Scholar 

  46. Papatheodoridis GV, Lampertico P, Manolakopoulos S, Lok A. Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review. J Hepatol. 2010;53(2):348–56.

    Article  PubMed  CAS  Google Scholar 

  47. Kim BK, Park JY, Kim do Y, et al. Persistent hepatitis B viral replication affects recurrence of hepatocellular carcinoma after curative resection. Liver Int. 2008;28(3):393–401.

    Article  PubMed  CAS  Google Scholar 

  48. Hung IF, Poon RT, Lai CL, Fung J, Fan ST, Yuen MF. Recurrence of hepatitis B-related ­hepatocellular carcinoma is associated with high viral load at the time of resection. Am J Gastroenterol. 2008;103(7):1663–73.

    Article  PubMed  Google Scholar 

  49. Williams IT, Bell BP, Kuhnert W, Alter MJ. Incidence and transmission patterns of acute hepatitis C in the United States, 1982–2006. Arch Intern Med. 2011;171(3):242–8.

    Article  PubMed  Google Scholar 

  50. Alter MJ. Healthcare should not be a vehicle for transmission of hepatitis C virus. J Hepatol. 2008;48(1):2–4.

    Article  PubMed  Google Scholar 

  51. Donahue JG, Munoz A, Ness PM, et al. The declining risk of post-transfusion hepatitis C virus infection. N Engl J Med. 1992;327(6):369–73.

    Article  PubMed  CAS  Google Scholar 

  52. Seeff LB. Natural history of chronic hepatitis C. Hepatology. 2002;36(5 Suppl 1):S35–46.

    Article  PubMed  Google Scholar 

  53. Poynard T, Moussalli J, Ratziu V, Regimbeau C, Opolon P. Effect of interferon therapy on the natural history of hepatitis C virus-related cirrhosis and hepatocellular carcinoma. Clin Liver Dis. 1999;3(4):869–81.

    Article  PubMed  CAS  Google Scholar 

  54. Yoshida H, Tateishi R, Arakawa Y, et al. Benefit of interferon therapy in hepatocellular carcinoma prevention for individual patients with chronic hepatitis C. Gut. 2004;53(3):425–30.

    Article  PubMed  CAS  Google Scholar 

  55. Masuzaki R, Yoshida H, Omata M. Interferon reduces the risk of hepatocellular carcinoma in hepatitis C virus-related chronic hepatitis/liver cirrhosis. Oncology. 2010;78 Suppl 1:17–23.

    Article  PubMed  CAS  Google Scholar 

  56. Heathcote EJ. Prevention of hepatitis C virus-related hepatocellular carcinoma. Gastroenterology. 2004;127(5 Suppl 1):S294–302.

    Article  PubMed  Google Scholar 

  57. Ueno Y, Sollano JD, Farrell GC. Prevention of hepatocellular carcinoma complicating chronic hepatitis C. J Gastroenterol Hepatol. 2009;24(4):531–6.

    Article  PubMed  CAS  Google Scholar 

  58. Nishiguchi S, Kuroki T, Nakatani S, et al. Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet. 1995;346(8982):1051–5.

    Article  PubMed  CAS  Google Scholar 

  59. Nishiguchi S, Shiomi S, Nakatani S, et al. Prevention of hepatocellular carcinoma in patients with chronic active hepatitis C and cirrhosis. Lancet. 2001;357(9251):196–7.

    Article  PubMed  CAS  Google Scholar 

  60. Mazella J, Botto JM, Guillemare E, Coppola T, Sarret P, Vincent JP. Structure, functional expression, and cerebral localization of the levocabastine-sensitive neurotensin/neuromedin N receptor from mouse brain. J Neurosci. 1996;16(18):5613–20.

    PubMed  CAS  Google Scholar 

  61. Bruno S, Silini E, Crosignani A, et al. Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: a prospective study. Hepatology. 1997;25(3):754–8.

    Article  PubMed  CAS  Google Scholar 

  62. Fattovich G, Giustina G, Degos F, et al. Effectiveness of interferon alfa on incidence of hepatocellular carcinoma and decompensation in cirrhosis type C. European Concerted Action on Viral Hepatitis (EUROHEP). J Hepatol. 1997;27(1):201–5.

    Article  PubMed  CAS  Google Scholar 

  63. Effect of interferon-alpha on progression of cirrhosis to hepatocellular carcinoma: a retrospective cohort study. International Interferon-alpha Hepatocellular Carcinoma Study Group. Lancet. 1998;351(9115):1535–39.

    Google Scholar 

  64. Imai Y, Kawata S, Tamura S, et al. Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C Osaka Hepatocellular Carcinoma Prevention Study Group. Ann Intern Med. 1998;129(2):94–9.

    PubMed  CAS  Google Scholar 

  65. Benvegnu L, Chemello L, Noventa F, Fattovich G, Pontisso P, Alberti A. Retrospective analysis of the effect of interferon therapy on the clinical outcome of patients with viral cirrhosis. Cancer. 1998;83(5):901–9.

    Article  PubMed  CAS  Google Scholar 

  66. Serfaty L, Aumaitre H, Chazouilleres O, et al. Determinants of outcome of compensated hepatitis C virus-related cirrhosis. Hepatology. 1998;27(5):1435–40.

    Article  PubMed  CAS  Google Scholar 

  67. Valla DC, Chevallier M, Marcellin P, et al. Treatment of hepatitis C virus-related cirrhosis: a randomized, controlled trial of interferon alfa-2b versus no treatment. Hepatology. 1999;29(6): 1870–5.

    Article  PubMed  CAS  Google Scholar 

  68. Okanoue T, Itoh Y, Minami M, et al. Interferon therapy lowers the rate of progression to hepatocellular carcinoma in chronic hepatitis C but not significantly in an advanced stage: a retrospective study in 1148 patients. Viral Hepatitis Therapy Study Group. J Hepatol. 1999;30(4):653–9.

    Article  PubMed  CAS  Google Scholar 

  69. Yoshida H, Shiratori Y, Moriyama M, et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy. Ann Intern Med. 1999;131(3):174–81.

    PubMed  CAS  Google Scholar 

  70. Singal AK, Singh A, Jaganmohan S, et al. Antiviral therapy reduces risk of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis. Clin Gastroenterol Hepatol. 2009;8(2):192–9.

    Article  PubMed  Google Scholar 

  71. Papatheodoridis GV, Papadimitropoulos VC, Hadziyannis SJ. Effect of interferon therapy on the development of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis: a meta-analysis. Aliment Pharmacol Ther. 2001;15(5):689–98.

    Article  PubMed  CAS  Google Scholar 

  72. Miyake Y, Iwasaki Y, Yamamoto K. Meta-analysis: reduced incidence of hepatocellular carcinoma in patients not responding to interferon therapy of chronic hepatitis C. Int J Cancer. 2010;127(4):989–96.

    PubMed  CAS  Google Scholar 

  73. Morgan TR, Ghany MG, Kim HY, et al. Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology. 2010;52(3):833–44.

    Article  PubMed  CAS  Google Scholar 

  74. Imai Y, Tamura S, Tanaka H, et al. Reduced risk of hepatocellular carcinoma after interferon therapy in aged patients with chronic hepatitis C is limited to sustained virological responders. J Viral Hepat. 2010;17(3):185–91.

    Article  PubMed  CAS  Google Scholar 

  75. Yu ML, Lin SM, Chuang WL, et al. A sustained virological response to interferon or interferon/ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: a nationwide, multicentre study in Taiwan. Antivir Ther. 2006;11(8):985–94.

    PubMed  CAS  Google Scholar 

  76. Di Bisceglie AM, Shiffman ML, Everson GT, et al. Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med. 2008;359(23):2429–41.

    Article  PubMed  Google Scholar 

  77. Afdhal NH, Levine R, Brown Jr R, Freilich B, O’brien M, Brass C. Colchicine versus peg-interferon Alfa 2B long term therapy: results of the 4 year copilot trial. Hepatology. 2008;48:S4.

    Google Scholar 

  78. Bruix J, Poynard T, Colombo M, et al. Maintenance therapy with peginterferon alfa-2b does not prevent hepatocellular carcinoma in cirrhotic patients with chronic hepatitis C. Gastroenterology. 2011;140(7):1990–9.

    Article  PubMed  CAS  Google Scholar 

  79. Lok AS, Everhart JE, Wright EC, et al. Maintenance Peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C. Gastroenterology. 2011;140(3):840–9.

    Article  PubMed  CAS  Google Scholar 

  80. Singal AK, Freeman Jr DH, Anand BS. Meta-analysis: interferon improves outcomes following ablation or resection of hepatocellular carcinoma. Aliment Pharmacol Ther. 2010;32(7):851–8.

    Article  PubMed  CAS  Google Scholar 

  81. McHutchison JG, Manns MP, Muir AJ, et al. Telaprevir for previously treated chronic HCV infection. N Engl J Med. 2011;362(14):1292–303.

    Article  Google Scholar 

  82. Pawlotsky JM. The Results of Phase III Clinical Trial With Telaprevir and Boceprevir Presented at the Liver Meeting 2010: A New Standard of Care for Hepatitis C Virus Genotype 1 Infection, But With Issues Still Pending. Gastroenterology. 2011 ;140(3):746–54.

    Google Scholar 

  83. Kowdley KV, Tait JF, Bennett RL, Motulsky AG. 1993. In:Pagon RA, Bird TD, Dolan CR, Stephens K, (eds.), GeneReviews. Seattle (WA) University of Washington, Seattle; 1993–2000.

    Google Scholar 

  84. Kowdley KV. Iron, hemochromatosis, and hepatocellular carcinoma. Gastroenterology. 2004;127(5 Suppl 1):S79–86.

    Article  PubMed  CAS  Google Scholar 

  85. Guyader D, Jacquelinet C, Moirand R, et al. Noninvasive prediction of fibrosis in C282Y homozygous hemochromatosis. Gastroenterology. 1998;115(4):929–36.

    Article  PubMed  CAS  Google Scholar 

  86. Harrison SA, Bacon BR. Relation of hemochromatosis with hepatocellular carcinoma: epidemiology, natural history, pathophysiology, screening, treatment, and prevention. Med Clin North Am. 2005;89(2):391–409.

    Article  PubMed  CAS  Google Scholar 

  87. Alexander J, Kowdley KV. HFE-associated hereditary hemochromatosis. Genet Med. 2009;11(5):307–13.

    Article  PubMed  Google Scholar 

  88. Nielsen P, Fischer R, Buggisch P, Janka-Schaub G. Effective treatment of hereditary haemochromatosis with desferrioxamine in selected cases. Br J Haematol. 2003;123(5):952–3.

    Article  PubMed  Google Scholar 

  89. Phatak PD, Bonkovsky HL, Kowdley KV. Hereditary hemochromatosis: time for targeted screening. Ann Intern Med. 2008;149(4):270–2.

    PubMed  Google Scholar 

  90. El-Serag HB, Inadomi JM, Kowdley KV. Screening for hereditary hemochromatosis in siblings and children of affected patients. A cost-effectiveness analysis. Ann Intern Med. 2000;132(4):261–9.

    PubMed  CAS  Google Scholar 

  91. Bring P, Partovi N, Ford JA, Yoshida EM. Iron overload disorders: treatment options for patients refractory to or intolerant of phlebotomy. Pharmacotherapy. 2008;28(3):331–42.

    Article  PubMed  CAS  Google Scholar 

  92. Powell EE, Cooksley WG, Hanson R, Searle J, Halliday JW, Powell LW. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology. 1990;11(1):74–80.

    Article  PubMed  Google Scholar 

  93. Adams LA, Lymp JF, St Sauver J, et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology. 2005;129(1):113–21.

    Article  PubMed  Google Scholar 

  94. Ratziu V, Bonyhay L, Di Martino V, et al. Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis. Hepatology. 2002;35(6):1485–93.

    Article  PubMed  Google Scholar 

  95. Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: A weighty connection. Hepatology. 2010;51(5):1820–32.

    Article  PubMed  Google Scholar 

  96. Ratziu V, Caldwell S, Neuschwander-Tetri BA. Therapeutic trials in nonalcoholic steatohepatitis: Insulin sensitizers and related methodological issues. Hepatology. 2010;52(6):2206–15.

    Article  PubMed  CAS  Google Scholar 

  97. Lok AS-F. Does antiviral therapy for hepatitis B and C prevent hepatocellular carcinoma? J Gastroenterol Hepatol. 2011;26(2):221–7.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Liver Center, Division of Gastroenterology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA

    Narayan Dharel MD & Daryl T. Lau MD, MSc, MPH

Authors
  1. Narayan Dharel MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Daryl T. Lau MD, MSc, MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Daryl T. Lau MD, MSc, MPH .

Editor information

Editors and Affiliations

  1. Medical Center, Center for Liver Disease, The University of Chicago, 5841 South Maryland Ave. MC 7120, Chicago, 60637, Illinois, USA

    Nancy Reau

  2. , Texas Liver Institute, University of Texas, 621 Camden St, #202, San Antonio, 78215, Texas, USA

    Fred Poordad

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer Science+Business Media New York

About this chapter

Cite this chapter

Dharel, N., Lau, D.T. (2012). The Impact of Treating Chronic Liver Diseases on Hepatocellular Carcinoma Prevention. In: Reau, N., Poordad, F. (eds) Primary Liver Cancer. Clinical Gastroenterology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-61779-863-4_12

Download citation

  • DOI: https://doi.org/10.1007/978-1-61779-863-4_12

  • Published:

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-61779-862-7

  • Online ISBN: 978-1-61779-863-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation